FDA Ends ANDA 'Reviews' To Streamline Approval Process
Executive Summary
Instead, US agency will conduct 'assessments' of generic drug applications, according to new MaPP.
You may also be interested in...
Vocabulary Change: CDER Eliminating 'Review' For NDAs And BLAs
Like ANDA evaluations, US FDA plans to use the word assessment to describe them for NDAs and BLAs.
Gottlieb Leaves FDA Feeling Good About Generic Approvals, But Concerned About Innovative Competition
In interview with the Pink Sheet, US FDA Commissioner Scott Gottlieb offers a final reflection of his time as commissioner.
Gottlieb Uses ASCO Platform To Unveil Two Pilot Programs To Speed Drug Review
US FDA commissioner outlines plans to allow partial submissions as soon as database locks and to create joint sponsor-agency review documents.